Weaver C. Barksdale & Associates, Inc. Bristol Myers Squibb CO Transaction History
Weaver C. Barksdale & Associates, Inc.
- $111 Million
- Q3 2024
A detailed history of Weaver C. Barksdale & Associates, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Weaver C. Barksdale & Associates, Inc. holds 19,580 shares of BMY stock, worth $1.14 Million. This represents 0.91% of its overall portfolio holdings.
Number of Shares
19,580
Previous 20,618
5.03%
Holding current value
$1.14 Million
Previous $856,000
18.34%
% of portfolio
0.91%
Previous 0.81%
Shares
12 transactions
Others Institutions Holding BMY
# of Institutions
2,533Shares Held
1.47BCall Options Held
31.6MPut Options Held
35M-
Vanguard Group Inc Valley Forge, PA189MShares$11 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY159MShares$9.24 Billion0.15% of portfolio
-
State Street Corp Boston, MA92.9MShares$5.41 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY77.9MShares$4.54 Billion0.33% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA61MShares$3.55 Billion0.61% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $124B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...